RxDoctor Payments Data

Emily Reljin

Psychiatric/Mental Health · Fairlawn, OHNPI 1851885651

Payments from drug & device makers

$974in general payments, 2019–2025

Across 34 payments — averaging $28.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$240
  • Alkermes, Inc.$163
  • AbbVie$124
  • Idorsia Pharmaceuticals US Inc$121
  • Sunovion Pharmaceuticals Inc.$100
  • Neurocrine Biosciences, Inc.$91
  • plus $134 from 4 others

What the payments were for

  • Food & beverage$974100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$974 in reported general payments places this provider in the 60th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$3,887
Medicare patients
17
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole41$119,055
IngrezzaValbenazine Tosylate12$100,133
Invega SustennaPaliperidone Palmitate14$49,121
RexultiBrexpiprazole21$35,827
VraylarCariprazine Hcl13$15,877
Aripiprazole56$5,552
Trazodone Hcl158$4,059
Asenapine Maleate18$2,954
Quetiapine Fumarate69$2,731
Atomoxetine Hcl13$2,590
Haloperidol Decanoate37$2,547
Hydroxyzine Pamoate94$2,340
Hydroxyzine Hcl77$2,190
Olanzapine77$2,076
Ziprasidone Hcl36$2,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$28$154,88262 claims
Neurocrine Biosciences, Inc.Ingrezza$91$100,13312 claims
Johnson & JohnsonInvega Sustenna$240$49,12114 claims
AbbVieVraylar$124$15,87713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Fairlawn

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →